In the murine models bearing a mixture of B-cell lymphoma lines composed of CD19 negative, CD20 negative, and CD22 negative variants, the trispecific duoCAR-T cells could efficiently kill tumor cells. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.